SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

IntraBiotics Pharmaceuticals, Inc.

 

(Exact name of registrant as specified in its charter)

Delaware		0-29993		94-3200380
(State or other jurisdiction of incorporation)		(Commission File Num		ber) (IRS Employer Identification No.)

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (925) 906-5331

Not Applicable

 

(Former name or former address, if changed since last report.)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02(b). Departure of Directors or Principal Officers;

     On December 1, 2005, Mr. Mark L. Perry provided IntraBiotics Pharmaceuticals, Inc. (the “Company”) with a notice of resignation from the Company’s Board of Directors and all committees of the Board effective as of such date.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.